High Vista Strategies LLC Immuno Gen, Inc. Transaction History

High Vista Strategies LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $2.04 Million - $2.88 Million	144,772 New	144,772 $2.3 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $567,056 - $818,940	-126,575 Reduced 66.02%	65,151 $311,000
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $359,200 - $656,824	114,032 Added 146.77%	191,726 $863,000
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $330,976 - $581,151	77,694 New	77,694 $370,000
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $114,418 - $180,660	-24,088 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $45,978 - $60,357	9,159 Added 61.35%	24,088 $137,000
Q1 2021 May 17, 2021	SELL	$6.5 - $10.53 $46,611 - $75,510	-7,171 Reduced 32.45%	14,929 $121,000
Q4 2020 Feb 16, 2021	SELL	$3.7 - $7.66 $17,390 - $36,002	-4,700 Reduced 17.54%	22,100 $143,000
Q3 2020 Nov 16, 2020	BUY	$3.45 - $4.89 $92,460 - $131,051	26,800 New	26,800 $96,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.